well the obvious difference is in performance. They didn't even apply to be a class 2 with fda. Yes, they may improve over time, but any successful model is going to face competition eventually. RAP has a very solid advantage in being diagnostically capable already
- Forums
- ASX - By Stock
- RAP
- Ann: At-Home Obstructive Sleep Apnoea Study Update
Ann: At-Home Obstructive Sleep Apnoea Study Update, page-200
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online